ArticleBMC nephrology2025
Association between serum uric acid levels and primary aldosteronism.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary aldosteronism (PA), the most common cause of secondary hypertension, is associated with increased cardiovascular risks compared to essential hypertension (EH). Although PA is frequently associated with metabolic abnormalities, the role of serum uric acid (SUA) remains unclear. This study aimed to evaluate SUA as a potential biomarker for distinguishing PA from EH.
methodsA retrospective analysis of 152 PA patients and 280 age-matched EH patients hospitalized between January 2019 and February 2024 was conducted. Biochemical and clinical parameters, including SUA, aldosterone-renin ratio (ARR), potassium, and metabolic markers, were analyzed. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses assessed SUA's diagnostic accuracy for PA. Subgroup analyses were conducted by sex and menopausal status. The disease severity of PA patients was further evaluated using the Primary Aldosteronism Severity Classification (PASC).
resultsPA patients exhibited significantly lower SUA levels compared to EH (P < 0.001), independent of age, BMI, and renal function. SUA levels showed a significant inverse correlation with PASC severity grades (Spearman's rho = -0.42, P < 0.001) and no significant difference was observed between APA and IHA subtypes. SUA ≤ 361 µmol/L was strongly associated with PA, with an ROC AUC of 0.750. The ROC curve analysis revealed an AUC of 0.766 for SUA in screening PA among males (optimal cut-off: 364 µmol/L). For premenopausal female patients, the AUC was 0.725 (cut-off: 325 µmol/L), and for postmenopausal females, the AUC was 0.764 (cut-off: 358 µmol/L). The diagnostic performance of SUA surpassed that of the PFK score (AUC: 0.732).
conclusionReduced SUA levels are independently associated with PA, suggesting its potential utility as an auxiliary biomarker to raise suspicion for PA, particularly in settings with limited access to ARR testing. Prospective studies are required to validate its clinical relevance and mechanistic basis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.